109 results about "Polycyclic Hydrocarbons" patented technology

A composition for blood serum or plasma separation which has improved compatibility between a cyclopentadiene oligomer and a phthalic ester and generates no oily ingredient suspending in the blood serum or plasma after centrifugal separation regardless of the conditions for the centrifugal separation; and a vessel for blood examination which contains the composition. The composition for blood serum or plasma separation comprises: a polycyclic hydrocarbon compound having an unsaturated and / or saturated cyclic structure in the molecule and having a solidifying point or pour point of 0 DEG C or lower; a cyclopentadiene oligomer; and a phthalic ester.

A particulate filter particularly suited for analytical gravimetric weighing applications is disclosed. The particulate filter includes a polytetrafluoroethylene (PTFE) media supported by a ring and yields stable microgram and submicrogram weighing results. The support ring may be PTFE, metal foil, or another non-hygroscopic polymer such that the mass of the filter does not vary with changes in atmospheric moisture. The filter simplifies the discharge of electrostatic charge buildup such that when a conductive filter media is combined with a conductive ring device, the discharge may be accomplished by placing the filter on a grounded weighing pan or other surface. The particulate filter can simplify filter identification by including identification symbols imprinted on each side of the filter media. Due to the chemically inert qualities of its components, the particulate filter is particularly suited for extraction techniques used during the detection of polycyclic hydrocarbons as is conducted in emissions and ambient air testing.

The present invention provides a flowable materials container. The container has a first sidewall and a second sidewall sealed together along a peripheral seam to define a fluid chamber. At least one sidewall is a film having at least one layer of blend of a first component selected from the group of: (1) ethylene and α-olefin copolymers having a density of less than about 0.915 g / cc, (2) ethylene copolymerized with lower alkyl acrylates, (3) ethylene copolymerized with lower alkyl substituted alkyl acrylates and (4) ionomers, the first component being present in an amount from about 99% to about 55% by weight of the blend, a second component in an amount by weight of the blend from about 45% to about 1% and consists of one or more polymers of the group: (1) propylene containing polymers, (2) polybutene polymers, (3) polymethylpentene polymers, (4) cyclic olefin containing polymers and (5) bridged polycyclic hydrocarbon containing polymers; and the film has a modulus of elasticity when measured in accordance with ASTM D882 of less than about 60,000 psi, an internal haze when measured in accordance with ASTM D1003 of less than about 25%, an internal adhesion ranking of greater than about 2, a sample creep at 120° C. under 27 psi loading of less than or equal to 150% for a film having a thickness of from about 5 mils to about 15 mils, and the film can be heat sealed into a container having seals wherein the seals remain intact when the container is autoclaved at 121° C. for one hour.

Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and / or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-stimulated growth of cells, and treating or preventing cancer, such as breast cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy.

Provided is a curable composition including (A) an addition reaction product of (a) a compound with 2 silicon atom-bonded hydrogen atoms within each molecule, having a general formula (1):wherein, A is a bivalent group represented by a formula (2):(wherein, R′ represents an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms, or an alkoxy group of 1 to 6 carbon atoms, and n represents an integer from 0 to 100), or a group having a structural formula (3):and each R represents an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms, or an alkoxy group of 1 to 6 carbon atoms, and (b) a polycyclic hydrocarbon with 2 addition reactive carbon-carbon double bonds within each molecule, said addition reaction product containing at least two addition reactive carbon-carbon double bonds in each molecule, (B) a compound with at least 3 silicon atom-bonded hydrogen atoms within each molecule, and (C) a hydrosilylation reaction catalyst. This composition is useful as a material for optical devices or parts, insulation material for electronic devices or parts, or coating material.

An organic light-emitting device comprising a light-emitting layer or a plurality of organic compound thin layers including a light-emitting layer formed between a pair of electrodes, wherein at least one layer comprises at least one kind of compound represented by the following formula (1):wherein R<11>, R<12 >and R<13 >each represents a group having a cyclocondensed polycyclic hydrocarbon structure in which three or more rings are cyclocondensed; and a novel cyclocondensed polycyclic hydrocarbon compound.